Ozempic Blindness Lawsuit Alleges Novo Nordisk Concealed NAION Risks
New filing from the mass tort press
Headline as published by AboutLawsuits.com on Oct 30, 2026; collected by the wire Oct 30, 2026, 2:15 PM ET.
Coverage
Named in this story
- MDLMDL 3094 · GLP-1 Receptor AgonistsMatched on
GLP-1
- MDLMDL 3163 · GLP-1 Vision Loss (NAION)Matched on
NAION
Topics
- Mass torts and MDLsMatched on
GLP-1
- Lawsuits and filingsMatched on
Lawsuit
Explore the named firms, organizations and MDL dockets above. Sources and method
MDL No. 3094
GLP-1 Receptor Agonists
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 4,025
Per the JPML pending-dockets report of October 1, 2026.
MDL No. 3163
GLP-1 Vision Loss (NAION)
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 247
Per the JPML pending-dockets report of October 1, 2026.